FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912393592> ?p ?o ?g. }

• W2912393592 endingPage "e0210891" @default.
• W2912393592 startingPage "e0210891" @default.
• W2912393592 abstract "Background This study evaluated the feasibility of achieving high response rates in stage II or III breast cancer by tailoring neoadjuvant therapy using clinical and histopathological features and the Oncotype DX Breast Recurrence Score. Genomic determinants of response and resistance were also explored. Patients and outcome measures Fifty-one patients were enrolled. The primary cohort comprised 40 patients: 15 human epidermal growth factor receptor type 2 (HER2)-amplified; 15 triple-negative (TNBC); and ten hormone receptor (HR)-positive, HER2-non-amplified tumours; with recurrence scores ≥25. Patients were treated with epirubicin and cyclophosphamide, followed by nab-paclitaxel, with the addition of trastuzumab if HER2-amplified. The primary endpoint was pathological complete response (pCR) in the breast. Pre- and post-treatment tumour samples underwent variant burden, gene and gene pathway, mutational signature profile and clonal evolution analyses. Results The pCR rates were: overall 55% (n = 22), HER2-amplified 80% (n = 12), triple-negative 46% (n = 7) and HR-positive, HER2-non-amplified 30% (n = 3). Grade 3 or 4 adverse events included febrile neutropenia (8%), neutropenia (18%), sensory neuropathy (5%), deranged transaminases (5%), fatigue (2%), diarrhoea (2%), and pneumothorax (2%). Molecular analyses demonstrated strong similarities between residual disease and matched primary tumour. ATM signalling pathway alterations and the presence of a COSMIC Signature 3 implied the majority of tumours contained some form of homologous repair deficiency. ATM pathway alterations were identified in the subset of TNBC patients who did not achieve pCR; Signature 3 was present in both pCR and non-pCR subgroups. Clonal evolution analyses demonstrated both persistence and emergence of chemoresistant clones. Conclusions This treatment regime resulted in a high rate of pCR, demonstrating that tailored neoadjuvant therapy using a genomic recurrence score is feasible and warrants further investigation. Molecular analysis revealed few commonalities between patients. For TNBC future clinical gains will require precision medicine, potentially using DNA sequencing to identify specific targets for individuals with resistant disease. Trial registration Clinicaltrials.gov NCT01830244" @default.
• W2912393592 created "2019-02-21" @default.
• W2912393592 creator A5001215942 @default.
• W2912393592 creator A5002536098 @default.
• W2912393592 creator A5004781307 @default.
• W2912393592 creator A5022244006 @default.
• W2912393592 creator A5025052420 @default.
• W2912393592 creator A5032945961 @default.
• W2912393592 creator A5047661247 @default.
• W2912393592 creator A5060696449 @default.
• W2912393592 creator A5060995273 @default.
• W2912393592 creator A5069656105 @default.
• W2912393592 creator A5071412298 @default.
• W2912393592 creator A5079225408 @default.
• W2912393592 creator A5079753000 @default.
• W2912393592 date "2019-02-14" @default.
• W2912393592 modified "2023-09-26" @default.
• W2912393592 title "Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trial—Clinical outcomes and molecular determinants of response" @default.
• W2912393592 cites W1526705543 @default.
• W2912393592 cites W1842792112 @default.
• W2912393592 cites W1919257374 @default.
• W2912393592 cites W2015485590 @default.
• W2912393592 cites W2032019813 @default.
• W2912393592 cites W2040730809 @default.
• W2912393592 cites W2044133019 @default.
• W2912393592 cites W2045777875 @default.
• W2912393592 cites W2075894019 @default.
• W2912393592 cites W2105496345 @default.
• W2912393592 cites W2110905563 @default.
• W2912393592 cites W2120742047 @default.
• W2912393592 cites W2133465414 @default.
• W2912393592 cites W2136464548 @default.
• W2912393592 cites W2142588358 @default.
• W2912393592 cites W2147411421 @default.
• W2912393592 cites W2147415463 @default.
• W2912393592 cites W2149441684 @default.
• W2912393592 cites W2150757282 @default.
• W2912393592 cites W2155943701 @default.
• W2912393592 cites W2158217645 @default.
• W2912393592 cites W2161382947 @default.
• W2912393592 cites W2210186184 @default.
• W2912393592 cites W2276335691 @default.
• W2912393592 cites W2295085830 @default.
• W2912393592 cites W2344657883 @default.
• W2912393592 cites W2402636472 @default.
• W2912393592 cites W2417483443 @default.
• W2912393592 cites W2469253047 @default.
• W2912393592 cites W2525265150 @default.
• W2912393592 cites W2563490856 @default.
• W2912393592 cites W2565436052 @default.
• W2912393592 cites W2566168881 @default.
• W2912393592 cites W2584632839 @default.
• W2912393592 cites W2587686129 @default.
• W2912393592 cites W2596164112 @default.
• W2912393592 cites W2602012552 @default.
• W2912393592 cites W2621170119 @default.
• W2912393592 cites W2746672093 @default.
• W2912393592 cites W2749641460 @default.
• W2912393592 cites W2771217224 @default.
• W2912393592 cites W2779333875 @default.
• W2912393592 cites W2779944044 @default.
• W2912393592 cites W2782124401 @default.
• W2912393592 cites W2782183686 @default.
• W2912393592 cites W2796160662 @default.
• W2912393592 cites W2805734855 @default.
• W2912393592 doi "https://doi.org/10.1371/journal.pone.0210891" @default.
• W2912393592 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6375556" @default.
• W2912393592 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30763338" @default.
• W2912393592 hasPublicationYear "2019" @default.
• W2912393592 type Work @default.
• W2912393592 sameAs 2912393592 @default.
• W2912393592 citedByCount "13" @default.
• W2912393592 countsByYear W29123935922019 @default.
• W2912393592 countsByYear W29123935922020 @default.
• W2912393592 countsByYear W29123935922021 @default.
• W2912393592 countsByYear W29123935922022 @default.
• W2912393592 crossrefType "journal-article" @default.
• W2912393592 hasAuthorship W2912393592A5001215942 @default.
• W2912393592 hasAuthorship W2912393592A5002536098 @default.
• W2912393592 hasAuthorship W2912393592A5004781307 @default.
• W2912393592 hasAuthorship W2912393592A5022244006 @default.
• W2912393592 hasAuthorship W2912393592A5025052420 @default.
• W2912393592 hasAuthorship W2912393592A5032945961 @default.
• W2912393592 hasAuthorship W2912393592A5047661247 @default.
• W2912393592 hasAuthorship W2912393592A5060696449 @default.
• W2912393592 hasAuthorship W2912393592A5060995273 @default.
• W2912393592 hasAuthorship W2912393592A5069656105 @default.
• W2912393592 hasAuthorship W2912393592A5071412298 @default.
• W2912393592 hasAuthorship W2912393592A5079225408 @default.
• W2912393592 hasAuthorship W2912393592A5079753000 @default.
• W2912393592 hasBestOaLocation W29123935921 @default.
• W2912393592 hasConcept C121608353 @default.
• W2912393592 hasConcept C126322002 @default.
• W2912393592 hasConcept C143998085 @default.
• W2912393592 hasConcept C2776694085 @default.
• W2912393592 hasConcept C2776755627 @default.
• W2912393592 hasConcept C2779786085 @default.
• W2912393592 hasConcept C2780835546 @default.

• next